carvykti success drives stock outlook By Investing.com
Legend Biotech Corp (NASDAQ:LEGN), a biopharmaceutical company specializing in novel cell therapies for oncology, has been making waves in the healthcare sector with its flagship product, Carvykti. As the company navigates a competitive landscape and regulatory challenges, investors and analysts are closely watching its performance and future prospects.
Company Overview and Market Position
Legend Biotech has established itself as a key player in the multiple myeloma (MM) treatment space, primarily due to the success of Carvykti. This chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated strong efficacy in treating MM, particularly in later lines of therapy. The company’s partnership with Johnson & Johnson, a leader in the…
